Skip to main content

Table 4 PK parameters for piperaquine in the presence and absence of KAF156

From: A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine

PK parametera (unit) 800 mg KAF156 + 1280 mg PPQ
N = 23 (mean, SD, CV%)
1280 mg PPQ
N = 24 (mean, SD, CV%)
Cmax (ng/mL) 409 ± 299 (73.2%) [n = 23] 233 ± 169 (72.3%) [n = 24]
AUClast (h µg/mL) 10.8 ± 6.14 (56.8%) [n = 22] 10.3 ± 4.16 (40.2%) [n = 23]
AUCinf (h µg/mL) 11.9 ± 5.25 (44.1%) [n = 19] 12.0 ± 5.31 (44.2%) [n = 17]
AUC0-24 h (h µg/mL) 2.94 ± 1.81 (61.5%) [n = 22] 2.09 ± 0.993 (47.4%) [n = 24]
AUC0-72 h (h µg/mL) 4.73 ± 2.89 (61.0%) [n = 22] 3.49 ± 1.56 (44.8%) [n = 24]
AUC0-168 h (h µg/mL) 6.35 ± 3.67 (57.9%) [n = 21] 4.82 ± 1.95 (40.4%) [n = 23]
Tmax (h) 3.00 (2.00–4.05) [n = 23] 4.00 (3.00–8.00) [n = 24]
T1/2 (h) 469 ± 170 (36.2%) [n = 19] 509 ± 142 (27.9%) [n = 17]
CL/F (mL/h) 127,000 ± 53,100 (41.7%) [n = 19] 126,000 ± 52,700 (41.9%) [n = 17]
Vz/F (L) 82,200 ± 34,500 (42.0%) [n = 19] 89,100 ± 32,800 (36.8%) [n = 17]
  1. Abbreviations as per Table 3
  2. aAll PK parameter values are presented as mean ± SD (CV%) [n] except Tmax which is presented as median (range) [n]. n is number of subjects providing reliable estimate of the parameter